NEW YORK (GenomeWeb) – Veracyte said today that Anthem has issued a positive coverage policy for its Afirma gene expression classifier (GEC) for use in thyroid cancer diagnosis.

The genomic test is designed to identify benign thyroid nodules in patients with indeterminate fine needle aspiration biopsy results. With the coverage policy, it is now available to Anthem's approximately 40 million members, Veracyte said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.